This segment focuses on the research, development, and commercialization of therapies for migraine treatment and prevention. Key activities include clinical trials for rimegepant (NURTEC ODT) for acute and preventive treatment, and zavegepant, which is in Phase III trials. The segment utilizes advanced drug discovery techniques and clinical trial methodologies to develop effective treatments. The primary therapeutic area is migraine, addressing a significant unmet medical need. The segment's market positioning is strengthened by its innovative approach to migraine treatment, offering both acute and preventive options. Future opportunities include expanding the indications for existing drugs and developing new migraine therapies. Regulatory aspects involve obtaining FDA approval for new drugs and indications. Partnerships with healthcare providers and telemedicine platforms, such as Cove, facilitate patient access and evaluation.

This segment encompasses the development of therapies for a range of neurological and neuropsychiatric disorders, including spinocerebellar ataxia (SCA), obsessive-compulsive disorder (OCD), and Alzheimer's disease. Research and development efforts focus on small molecule therapeutics like Troriluzole and other product candidates such as BHV-0223 for amyotrophic lateral sclerosis (ALS), BHV-5000/5500 for neuropsychiatric indications, and Verdiperstat for multiple system atrophy (MSA) and ALS. The segment utilizes advanced drug discovery platforms and clinical trial methodologies to address these complex conditions. The patient impact is significant, as these therapies aim to improve the quality of life for individuals suffering from debilitating neurological and psychiatric illnesses. Market positioning is based on addressing unmet needs in these therapeutic areas. Future opportunities include expanding the pipeline with new drug candidates and exploring new indications for existing drugs. Regulatory aspects involve obtaining FDA approval for new drugs and indications. The segment may involve collaborations with research institutions and patient advocacy groups.